Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Gilead Sciences, Inc. (GILD)

61.69   -1.38 (-2.19%) 10-02 22:10
Open: 63.16 Pre. Close: 63.07
High: 63.58 Low: 61.61
Volume: 8,794,843 Market Cap: 77,320(M)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 63.61 - 64.03 64.03 - 64.39
Low: 60.8 - 61.21 61.21 - 61.55
Close: 61.09 - 61.76 61.76 - 62.31

Technical analysis

as of: 2022-09-30 4:28:30 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 77.15     One year: 80.45
Support: Support1: 61.47    Support2: 51.15
Resistance: Resistance1: 66.05    Resistance2: 68.87
Pivot: 64.2
Moving Average: MA(5): 62.73     MA(20): 64.27
MA(100): 62.76     MA(250): 64.37
MACD: MACD(12,26): -0.4     Signal(9): 0
Stochastic oscillator: %K(14,3): 13.6     %D(3): 13.7
RSI: RSI(14): 40.6
52-week: High: 74.12  Low: 57.16
Average Vol(K): 3-Month: 6,815 (K)  10-Days: 7,028 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GILD ] has closed above bottom band by 10.3%. Bollinger Bands are 21.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 01 Oct 2022
The past five years for Gilead Sciences (NASDAQ:GILD) investors has not been profitable - Simply Wall St

Thu, 29 Sep 2022
Gilead (NASDAQ: GILD) Ups the Ante Against Counterfeit HIV Drug Ring - TipRanks

Tue, 27 Sep 2022
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Nasdaq

Fri, 23 Sep 2022
2 Ports In The Storm: GILD And BMY Offer A Haven In A Turbulent Market - Forbes

Wed, 21 Sep 2022
Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know - Nasdaq

Mon, 19 Sep 2022
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 1,250 (M)
Shares Float 1,250 (M)
% Held by Insiders 0 (%)
% Held by Institutions 82.4 (%)
Shares Short 16,770 (K)
Shares Short P.Month 14,160 (K)

Stock Financials

EPS 3.26
EPS Est Next Qtl 1.89
EPS Est This Year 8.78
EPS Est Next Year 7.34
Book Value (p.s.) 16.13
Profit Margin (%) 15
Operating Margin (%) 40.3
Return on Assets (ttm) 10.6
Return on Equity (ttm) 20.5
Qtrly Rev. Growth 0.6
Gross Profit (p.s.) 17.42
Sales Per Share 22.01
EBITDA (p.s.) 10.56
Qtrly Earnings Growth -24.8
Operating Cash Flow 10,100 (M)
Levered Free Cash Flow 8,680 (M)

Stock Valuations

PE Ratio 18.86
PEG Ratio -8.1
Price to Book value 3.82
Price to Sales 2.8
Price to Cash Flow 7.63

Stock Dividends

Dividend 0.73
Forward Dividend 0
Dividend Yield 1.1%
Dividend Pay Date 2021-12-29
Ex-Dividend Date 2021-12-13
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.